The funding program supports the development of novel therapeutics (small molecule or biologic), medical devices and diagnostics for unmet medical needs, as well as repurposing of existing drugs for new indications. The program aims at the validation of research findings and translation into therapies, products or services. Only Scientists and Clinicians from BIH, Charité and MDC are eligible to apply.
We offer funding and mentoring to de-risk projects with high potential impact, addressing critical unmet medical needs for any indication. We help you to establish Intellectual Property and to learn what translation is all about. Selected projects become part of the SPARK-BIH program.
Finde here more information about the SPARK-BIH program
Two tracks of funding
The funding program consists of two different tracks and funding is strictly milestone-based.
- Track 1 projects are usually earlier in the development timeline and track 1 funding covers projects with a budget of up to 50k € for one year.
- Track 2 projects are further along the development timeline and must meet strict requirements regarding intellectual property rights and market access strategies. Funding covers projects with a financial need of more than 50k € for up to two years.
Some examples of past and current projects include unmet needs in pediatric, neglected or orphan diseases, cardiovascular, oncology, inflammatory, respiratory, neurological, autoimmune indications and infectious disease. We will consider small molecule, biologics, medical device, as well as diagnostics applications in these areas and other indications of serious unmet medical need.
The BIH seeks to increase the diversity of its funding programs. Women, individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities are especially encouraged to apply for BIH programs.